Literature DB >> 19085909

Natural killer cell function is intact after direct exposure to infectious hepatitis C virions.

Joo Chun Yoon1, Masaaki Shiina, Golo Ahlenstiel, Barbara Rehermann.   

Abstract

UNLABELLED: Although hepatitis C virus (HCV) has been shown to readily escape from virus-specific T and B cell responses, its effects on natural killer (NK) cells are less clear. Based on two previous reports that recombinant, truncated HCV E2 protein inhibits NK cell functions via crosslinking of CD81, it is now widely believed that HCV impairs NK cells as a means to establish persistence. However, the relevance of these findings has not been verified with HCV E2 expressed as part of intact virions. Here we employed a new cell culture system generating infectious HCV particles with genotype 1a and 2a structural proteins, and analyzed direct and indirect effects of HCV on human NK cells. Antibody-mediated crosslinking of CD16 stimulated and antibody-mediated crosslinking of CD81 inhibited NK cell activation and interferon gamma (IFN-gamma) production. However, infectious HCV itself had no effect even at titers that far exceeded HCV RNA and protein concentrations in the blood of infected patients. Consistent with these results, anti-CD81 but not HCV inhibited NK cell cytotoxicity. These results were independent of the presence or absence of HCV-binding antibodies and independent of the presence or absence of other peripheral blood mononuclear cell populations.
CONCLUSION: HCV 1a or 2a envelope proteins do not modulate NK cell function when expressed as a part of infectious HCV particles. Without direct inhibition by HCV, NK cells may become activated by cytokines in acute HCV infection and contribute to infection outcome and disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19085909      PMCID: PMC2695257          DOI: 10.1002/hep.22624

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  37 in total

Review 1.  NK cell and DC interactions.

Authors:  Megan A Cooper; Todd A Fehniger; Anja Fuchs; Marco Colonna; Michael A Caligiuri
Journal:  Trends Immunol       Date:  2004-01       Impact factor: 16.687

2.  Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C.

Authors:  A Takaki; M Wiese; G Maertens; E Depla; U Seifert; A Liebetrau; J L Miller; M P Manns; B Rehermann
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

3.  Natural cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) is not impaired in patients suffering from chronic hepatitis C.

Authors:  U Düesberg; A M Schneiders; D Flieger; G Inchauspé; T Sauerbruch; U Spengler
Journal:  J Hepatol       Date:  2001-11       Impact factor: 25.083

4.  Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity.

Authors:  Kerstin Herzer; Christine S Falk; Jens Encke; Sören T Eichhorst; Axel Ulsenheimer; Barbara Seliger; Peter H Krammer
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

5.  Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication.

Authors:  Magali Bouvier-Alias; Keyur Patel; Harel Dahari; Stéphanie Beaucourt; Patrick Larderie; Lawrence Blatt; Christophe Hezode; Gaston Picchio; Daniel Dhumeaux; Avidan U Neumann; John G McHutchison; Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425

6.  CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells.

Authors:  Simona Sivori; Michela Falco; Mariella Della Chiesa; Simona Carlomagno; Massimo Vitale; Lorenzo Moretta; Alessandro Moretta
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-24       Impact factor: 11.205

7.  Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses.

Authors:  Golo Ahlenstiel; Maureen P Martin; Xiaojiang Gao; Mary Carrington; Barbara Rehermann
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

8.  Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein.

Authors:  Stefania Crotta; Annalisa Stilla; Andreas Wack; Annalisa D'Andrea; Sandra Nuti; Ugo D'Oro; Marta Mosca; Franco Filliponi; R Maurizia Brunetto; Ferruccio Bonino; Sergio Abrignani; Nicholas M Valiante
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

9.  Determinants of viral clearance and persistence during acute hepatitis C virus infection.

Authors:  R Thimme; D Oldach; K M Chang; C Steiger; S C Ray; F V Chisari
Journal:  J Exp Med       Date:  2001-11-19       Impact factor: 14.307

10.  Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions.

Authors:  Chien-Te K Tseng; Gary R Klimpel
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

View more
  48 in total

1.  Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity.

Authors:  Philipp A Lang; Karl S Lang; Haifeng C Xu; Melanie Grusdat; Ian A Parish; Mike Recher; Alisha R Elford; Salim Dhanji; Namir Shaabani; Charles W Tran; Dilan Dissanayake; Ramtin Rahbar; Magar Ghazarian; Anne Brüstle; Jason Fine; Peter Chen; Casey T Weaver; Christoph Klose; Andreas Diefenbach; Dieter Häussinger; James R Carlyle; Susan M Kaech; Tak W Mak; Pamela S Ohashi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-13       Impact factor: 11.205

2.  Cell-to-cell contact with hepatitis C virus-infected cells reduces functional capacity of natural killer cells.

Authors:  Joo Chun Yoon; Jong-Baeck Lim; Jeon Han Park; Jae Myun Lee
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

3.  Monocytes activate natural killer cells via inflammasome-induced interleukin 18 in response to hepatitis C virus replication.

Authors:  Elisavet Serti; Jens M Werner; Michael Chattergoon; Andrea L Cox; Volker Lohmann; Barbara Rehermann
Journal:  Gastroenterology       Date:  2014-03-28       Impact factor: 22.682

Review 4.  Roles of liver innate immune cells in nonalcoholic fatty liver disease.

Authors:  Yu-Tao Zhan; Wei An
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

Review 5.  Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells.

Authors:  Barbara Rehermann
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

6.  Non-neutralizing epitopes induce robust hepatitis C virus (HCV)-specific antibody-dependent CD56+ natural killer cell responses in chronic HCV-infected patients.

Authors:  L Long; M Jia; X Fan; H Liang; J Wang; L Zhu; Z Xie; T Shen
Journal:  Clin Exp Immunol       Date:  2017-04-07       Impact factor: 4.330

7.  Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses.

Authors:  Sandy Pelletier; Christian Drouin; Nathalie Bédard; Salim I Khakoo; Julie Bruneau; Naglaa H Shoukry
Journal:  J Hepatol       Date:  2010-07-17       Impact factor: 25.083

8.  Activation of natural killer cells by hepatitis C virus particles in vitro.

Authors:  M M S Farag; K Weigand; J Encke; F Momburg
Journal:  Clin Exp Immunol       Date:  2011-06-17       Impact factor: 4.330

9.  Activation of natural killer cells during acute infection with hepatitis C virus.

Authors:  Barbara Amadei; Simona Urbani; Angelica Cazaly; Paola Fisicaro; Alessandro Zerbini; Parvin Ahmed; Gabriele Missale; Carlo Ferrari; Salim I Khakoo
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

10.  Long-term effect on natural killer cells by interferon-α therapy on the outcomes of HCV infection.

Authors:  Xiaoli Hu; Yanfang Jiang; Xiurong Li; Yanhang Gao; Xiaoli Guo; Xiumei Chi; Hongqing Yan; Junyan Feng; Jin Zhong; Bing Sun; Xue Shao; Weihua Xiao; Yu Pan; Junqi Niu
Journal:  J Interferon Cytokine Res       Date:  2013-12-24       Impact factor: 2.607

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.